Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Crosses Below 50-Day Moving Average – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price crossed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $15.46 and traded as low as $14.99. Ascentage Pharma Group International shares last traded at $15.00, with a volume of 7,313 shares traded.

Analyst Ratings Changes

A number of analysts have recently weighed in on AAPG shares. Citigroup assumed coverage on Ascentage Pharma Group International in a research report on Wednesday, October 14th. They set a “buy” rating and a $46.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a report on Thursday, October 8th. BTIG Research reiterated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. William Blair started coverage on Ascentage Pharma Group International in a research note on Friday, October 16th. They set an “outperform” rating for the company. Finally, Citizens Jmp assumed coverage on Ascentage Pharma Group International in a report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $43.44.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The business’s 50 day moving average is $15.46 and its 200 day moving average is $19.72.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The company had revenue of $22.24 million during the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.